Home Cart Sign in  
Chemical Structure| 2091134-68-6 Chemical Structure| 2091134-68-6

Structure of Golidocitinib
CAS No.: 2091134-68-6

Chemical Structure| 2091134-68-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AZD-4205 is a selective JAK1 inhibitor, with an IC50 of 73 nM, weakly inhibits JAK2, and shows little inhibition on JAK3 (IC50, >14.7, >30 μM, respectively).

Synonyms: AZD4205

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Golidocitinib

CAS No. :2091134-68-6
Formula : C25H31N9O2
M.W : 489.57
SMILES Code : O=C(NC1=CC=CC2=C1NC=C2C3=NC(NC4=CN(C)N=C4OC)=NC=C3)[C@@H](C)N5CCN(C)CC5
Synonyms :
AZD4205
MDL No. :N/A

Safety of Golidocitinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of Golidocitinib

epigenetics
RTK
JAK-STAT

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT06511869 Peripheral T-cell Lymphoma PHASE2 ACTIVE_NOT_RECRUITING 2025-03-26 Anhui Provincial Hospital (The... More >> First Affiliated Hospital of USTC), Hefei, Anhui, China|Peking university Third Hospital, Beijing, Beijing, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China|Hainan General Hospital, Haikou, Hainan, China|The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Hubei Cancer Hospital, Wuhan, Hubei, China|Union Hospital Tongji Medical College Huazhong University of Science and Thechnology, Wuhan, Hubei, China|Hunan Cancer Hospital, Changsha, Hunan, China|Reasearch Center of Clinical Trials, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China|The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China|The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|Shandong Cancer Hospital & Insititution, Jinan, Shandong, China|Linyi Cancer Hospital, Linyi, Shandong, China|Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China|Yunnan Cancer Hospital, Kunming, Yunan, China|The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China Less <<
NCT06511895 Peripheral T Cell Lymphoma PHASE2 RECRUITING 2025-12-26 Anhui Provincial Hospital (The... More >> First Affiliated Hospital of USTC), Hefei, Anhui, China|The Second Hospital of Anhui Meidcine University, Hefei, Anhui, China|Beijing Cancer Hospital, Beijing, Beijing, China|Peking University Third Hospital, Beijing, Beijing, China|Chongqing Cancer Hospital, Chongqing, Chongqing, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Hainan General Hospital, Haikou, Hainan, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China|Hunan Cancer Hospital, Changsha, Hunan, China|Jiangsu Cancer Hospital, Nanjing, Jiangsu, China|The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|The First Bethune Hospital of Jilin University, Changchun, Jilin, China|Shandong Cancer Hospital & Insititution, Jinan, Shandong, China|Ruijing Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China Less <<
NCT03450330 Nonsmall Cell Lung Cancer PHASE1|PHASE2 COMPLETED 2020-01-10 St George Hospital, Sydney, Ne... More >>w South Wales, Australia|Austin Hospital, Heidelberg, Victoria, 3084, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Northern Cancer Institute St Leonards, Sydney, 2066, Australia Less <<
NCT04105010 Relapsed or Refractory Periphe... More >>ral T Cell Lymphoma Less << PHASE2 COMPLETED 2024-02-22 Yale Cancer Center, New Haven,... More >> Connecticut, 06510, United States|Winship Cancer Institute, Atlanta, Georgia, 30322, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Epworth Hospital, East Melbourne, Australia|St Vincent's Hospital Melbourne, Fitzroy, Australia|Royal Hobart Hospital, Hobart, Australia|St George Hospital, Kogarah, Australia|Royal Perth Hospital, Perth, Australia|Westmead Hospital, Westmead, Australia|Beijing Cancer Hospital, Beijing, China|Beijing Friendship Hospital, Capital Medical University, Beijing, China|Beijing Hospital, Beijing, China|Peking University Third Hospital, Beijing, China|The First Hospital of Jilin University, Changchun, China|Hunan Cancer Hospital, Changsha, China|Xiangya Hospital Central South University, Changsha, China|Sichuan University - West China Hospital, Chengdu, China|Chongqing University Cancer Hospital, Chongqing, China|The Second Hospital of Dalian Medical University, Dalian, China|Guangdong Provincial People's Hospital, Guangzhou, China|NanFang Hospital of Southern Medical University, Guangzhou, China|Sun Yat-sen University Cancer Center, Guangzhou, China|Hainan General Hospital, Haikou, China|The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China|Zhejiang Cancer Hospital, Hangzhou, China|Anhui Provincial Cancer Hospital, Hefei, China|The Second Hospital of Anhui Medical University, Hefei, China|Shandong Cancer Hospital, Jinan, China|The First Hospital of Lanzhou University, Lanzhou, China|Linyi Cancer Hospital, Linyi, China|Jiangxi Province Cancer Hospital, Nanchang, China|The First Affiliated Hospital of Nanchang University, Nanchang, China|Jiangsu Cancer Hospital, Nanjing, China|Fudan University Shanghai Cancer Center, Shanghai, China|Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China|The First Affiliated Hospital of Soochow University, Suzhou, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China|The First Affiliated Hospital of Xiamen University, Xiamen, China|Henan Cancer Hospital, Zhengzhou, China|Inje University Busan Paik Hospital, Busan, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Keimyung University Dongsan Hospital, Daegu, Korea, Republic of|National Cancer Center, Goyang, Korea, Republic of|Chonbuk National University Hospital, Jeonju, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Samsung Medical Center, Seoul, 06133, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.04mL

0.41mL

0.20mL

10.21mL

2.04mL

1.02mL

20.43mL

4.09mL

2.04mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories